Get started
Author

Massimo Aglietta

Observed names: Aglietta, Massimo, M Aglietta, M. Aglietta
ORCID: 0000-0002-3616-7377
Observed ORCID: 0000-0002-3616-7377
OpenAlex ID: A5102816046
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
2020 · Chiara Cremolini, Carlotta Antoniotti, et al. · The Lancet Oncology · 353
PDF
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
2022 · T. André, S. Lonardi, et al. · Annals of Oncology · 289
PDF
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
2022 · Daniele Rossini, Carlotta Antoniotti, et al. · Journal of Clinical Oncology · 83
PDF
Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
2020 · Heinz-Josef Lenz, Sara Lonardi, et al. · Journal of Clinical Oncology · 60
Melanoma Brain Metastases in the Era of Target Therapies: An Overview
2020 · Paolo Becco, Susanna Gallo, et al. · Cancers · 49
PDF
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II)
2020 · Victoria Atkinson, Shahneen Sandhu, et al. · Melanoma Research · 39
Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
2019 · Michael J. Overman, Sara Lonardi, et al. · Journal of Clinical Oncology · 38
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib
2020 · Andrea Sartore-Bianchi, Sara Lonardi, et al. · JAMA Oncology · 31
PDF
Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
2022 · Alessandro Nepote, Gianluca Avallone, et al. · Journal of Clinical Medicine · 29
PDF
High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients
2021 · E. Berrino, A. Balsamo, et al. · ESMO Open · 21
PDF
Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)
2022 · Pasquale Lombardi, Giacomo Aimar, et al. · Oncology Reports · 19
PDF
Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.
2021 · Heinz-Josef Lenz, Sara Lonardi, et al. · Journal of Clinical Oncology · 19
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
2021 · Gerardo Rosati, Sara Lonardi, et al. · European Journal of Cancer · 17
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
2019 · Heinz-Josef Lenz, Sara Lonardi, et al. · Journal of Clinical Oncology · 17
Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).
2013 · Anna Maria Di Giacomo, Antonio M Grimaldi, et al. · Journal of Clinical Oncology · 14
Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).
2013 · Silvia Marsoni, Andrea Bertotti, et al. · Journal of Clinical Oncology · 12
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
2021 · Victoria G. Atkinson, Pietro Quaglino, et al. · Cancers · 11
PDF
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).
2013 · Paolo Antonio Ascierto, Ester Simeone, et al. · Journal of Clinical Oncology · 11
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial
2020 · Sandro Barni, Gerardo Rosati, et al. · Therapeutic Advances in Medical Oncology · 10
PDF
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
2013 · Paola Queirolo, Francesco Spagnolo, et al. · Journal of Clinical Oncology · 10
Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.
2017 · Scott Kopetz, Sara Lonardi, et al. · Journal of Clinical Oncology · 9
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
2021 · Massimo Aglietta, Vanna Chiarion-Sileni, et al. · Targeted Oncology · 7
PDF
Outcomes in patients with BRAF V600 –mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib
2023 · Massimo Aglietta, Vanna Chiarion-Sileni, et al. · Tumori Journal · 6
PDF
2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)
2015 · S. Cascinu, S. Lonardi, et al. · European Journal of Cancer · 5
Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP).
2013 · Vanna Chiarion-Sileni, Jacopo Pigozzo, et al. · Journal of Clinical Oncology · 5
Works count: 40
Citation count: 1,186
H-index: 14
I10-index: 20
Year
Topic
Type